Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals

Lorenzo Piemonti, Giliola Calori, Guido Lattuada, Alessia Mercalli, Francesca Ragogna, Maria Paola Garancini, Giacomo Ruotolo, Livio Luzi, Gianluca Perseghin

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

OBJECTIVE - Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemokine involved into the pathogenesis of atherosclerosis and has prognostic value in the acute and chronic phases in patients with acute coronary syndromes. RESEARCH DESIGN AND METHODS - MCP-1/CCL2 concentration was measured in plasma fractions of 363 middle-aged overweight/obese individuals (aged 61 ± 12 years, BMI 30.1 ± 6.6 kg/m 2, 15% with type 2 diabetes, and 12% with impaired glucose tolerance) of a population survey carried out in 1990-1991 in Lombardy, Italy (Cremona Study), and cardiovascular disease (CVD) mortality was assessed in 2006 through Regional Health Registry files. RESULTS - At baseline MCP-1/CCL2 was increased in individuals with type 2 diabetes (P <0.05) and showed significant correlations with biochemical risk markers of atherosclerosis. After 15 years, among the 363 subjects, there were 82 deaths due to CVD. In univariate analysis age, sex, fasting glucose and insulin, fibrinogen, glucose tolerance status, smoking habit, and MCP-1/CCL2 were associated with CVD mortality. Age, sex, fasting serum glucose, MCP-1/CCL2, and smoking habit maintained an independent association with CVD mortality in multiple regression analysis. In a subgroup of 113 subjects in whom data for C-reactive protein (CRP) were available, its level was not predictive of CVD mortality. CONCLUSIONS - In middle-aged overweight/obese individuals MCP-1/CCL2 was independently associated with CVD mortality. Further studies will be necessary to establish its role as a surrogate biomarker and as a potential therapeutic target.

Original languageEnglish
Pages (from-to)2105-2110
Number of pages6
JournalDiabetes Care
Volume32
Issue number11
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Chemokine CCL2
Blood Proteins
Cardiovascular Diseases
Mortality
Glucose
Type 2 Diabetes Mellitus
Habits
Fasting
Atherosclerosis
Biomarkers
Smoking
Glucose Intolerance
Acute Coronary Syndrome
Chemokines
C-Reactive Protein
Fibrinogen
Italy
Registries
Research Design
Regression Analysis

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. / Piemonti, Lorenzo; Calori, Giliola; Lattuada, Guido; Mercalli, Alessia; Ragogna, Francesca; Garancini, Maria Paola; Ruotolo, Giacomo; Luzi, Livio; Perseghin, Gianluca.

In: Diabetes Care, Vol. 32, No. 11, 11.2009, p. 2105-2110.

Research output: Contribution to journalArticle

Piemonti, Lorenzo ; Calori, Giliola ; Lattuada, Guido ; Mercalli, Alessia ; Ragogna, Francesca ; Garancini, Maria Paola ; Ruotolo, Giacomo ; Luzi, Livio ; Perseghin, Gianluca. / Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. In: Diabetes Care. 2009 ; Vol. 32, No. 11. pp. 2105-2110.
@article{d8b29c024d8c440385882f3fb2c2e3e7,
title = "Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals",
abstract = "OBJECTIVE - Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemokine involved into the pathogenesis of atherosclerosis and has prognostic value in the acute and chronic phases in patients with acute coronary syndromes. RESEARCH DESIGN AND METHODS - MCP-1/CCL2 concentration was measured in plasma fractions of 363 middle-aged overweight/obese individuals (aged 61 ± 12 years, BMI 30.1 ± 6.6 kg/m 2, 15{\%} with type 2 diabetes, and 12{\%} with impaired glucose tolerance) of a population survey carried out in 1990-1991 in Lombardy, Italy (Cremona Study), and cardiovascular disease (CVD) mortality was assessed in 2006 through Regional Health Registry files. RESULTS - At baseline MCP-1/CCL2 was increased in individuals with type 2 diabetes (P <0.05) and showed significant correlations with biochemical risk markers of atherosclerosis. After 15 years, among the 363 subjects, there were 82 deaths due to CVD. In univariate analysis age, sex, fasting glucose and insulin, fibrinogen, glucose tolerance status, smoking habit, and MCP-1/CCL2 were associated with CVD mortality. Age, sex, fasting serum glucose, MCP-1/CCL2, and smoking habit maintained an independent association with CVD mortality in multiple regression analysis. In a subgroup of 113 subjects in whom data for C-reactive protein (CRP) were available, its level was not predictive of CVD mortality. CONCLUSIONS - In middle-aged overweight/obese individuals MCP-1/CCL2 was independently associated with CVD mortality. Further studies will be necessary to establish its role as a surrogate biomarker and as a potential therapeutic target.",
author = "Lorenzo Piemonti and Giliola Calori and Guido Lattuada and Alessia Mercalli and Francesca Ragogna and Garancini, {Maria Paola} and Giacomo Ruotolo and Livio Luzi and Gianluca Perseghin",
year = "2009",
month = "11",
doi = "10.2337/dc09-0763",
language = "English",
volume = "32",
pages = "2105--2110",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals

AU - Piemonti, Lorenzo

AU - Calori, Giliola

AU - Lattuada, Guido

AU - Mercalli, Alessia

AU - Ragogna, Francesca

AU - Garancini, Maria Paola

AU - Ruotolo, Giacomo

AU - Luzi, Livio

AU - Perseghin, Gianluca

PY - 2009/11

Y1 - 2009/11

N2 - OBJECTIVE - Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemokine involved into the pathogenesis of atherosclerosis and has prognostic value in the acute and chronic phases in patients with acute coronary syndromes. RESEARCH DESIGN AND METHODS - MCP-1/CCL2 concentration was measured in plasma fractions of 363 middle-aged overweight/obese individuals (aged 61 ± 12 years, BMI 30.1 ± 6.6 kg/m 2, 15% with type 2 diabetes, and 12% with impaired glucose tolerance) of a population survey carried out in 1990-1991 in Lombardy, Italy (Cremona Study), and cardiovascular disease (CVD) mortality was assessed in 2006 through Regional Health Registry files. RESULTS - At baseline MCP-1/CCL2 was increased in individuals with type 2 diabetes (P <0.05) and showed significant correlations with biochemical risk markers of atherosclerosis. After 15 years, among the 363 subjects, there were 82 deaths due to CVD. In univariate analysis age, sex, fasting glucose and insulin, fibrinogen, glucose tolerance status, smoking habit, and MCP-1/CCL2 were associated with CVD mortality. Age, sex, fasting serum glucose, MCP-1/CCL2, and smoking habit maintained an independent association with CVD mortality in multiple regression analysis. In a subgroup of 113 subjects in whom data for C-reactive protein (CRP) were available, its level was not predictive of CVD mortality. CONCLUSIONS - In middle-aged overweight/obese individuals MCP-1/CCL2 was independently associated with CVD mortality. Further studies will be necessary to establish its role as a surrogate biomarker and as a potential therapeutic target.

AB - OBJECTIVE - Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemokine involved into the pathogenesis of atherosclerosis and has prognostic value in the acute and chronic phases in patients with acute coronary syndromes. RESEARCH DESIGN AND METHODS - MCP-1/CCL2 concentration was measured in plasma fractions of 363 middle-aged overweight/obese individuals (aged 61 ± 12 years, BMI 30.1 ± 6.6 kg/m 2, 15% with type 2 diabetes, and 12% with impaired glucose tolerance) of a population survey carried out in 1990-1991 in Lombardy, Italy (Cremona Study), and cardiovascular disease (CVD) mortality was assessed in 2006 through Regional Health Registry files. RESULTS - At baseline MCP-1/CCL2 was increased in individuals with type 2 diabetes (P <0.05) and showed significant correlations with biochemical risk markers of atherosclerosis. After 15 years, among the 363 subjects, there were 82 deaths due to CVD. In univariate analysis age, sex, fasting glucose and insulin, fibrinogen, glucose tolerance status, smoking habit, and MCP-1/CCL2 were associated with CVD mortality. Age, sex, fasting serum glucose, MCP-1/CCL2, and smoking habit maintained an independent association with CVD mortality in multiple regression analysis. In a subgroup of 113 subjects in whom data for C-reactive protein (CRP) were available, its level was not predictive of CVD mortality. CONCLUSIONS - In middle-aged overweight/obese individuals MCP-1/CCL2 was independently associated with CVD mortality. Further studies will be necessary to establish its role as a surrogate biomarker and as a potential therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=70449412663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449412663&partnerID=8YFLogxK

U2 - 10.2337/dc09-0763

DO - 10.2337/dc09-0763

M3 - Article

C2 - 19641159

AN - SCOPUS:70449412663

VL - 32

SP - 2105

EP - 2110

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -